Home Cart Sign in  
Chemical Structure| 1139-83-9 Chemical Structure| 1139-83-9

Structure of Urolithin B
CAS No.: 1139-83-9

Chemical Structure| 1139-83-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Urolithin B is a natural product with anti-proliferative and antioxidant activity, which can penetrate the blood-brain barrier and may have neuroprotective effects against Alzheimer’s Disease.It inhibits aromatase activity in human placental microsomes and aromatase-sensitive MCF-7 (MCF-7aro) human breast cancer cells when used at concentrations of 47 and 4.7 µM, respectively.

Synonyms: NSC 94726; 3-hydroxy Urolithin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Urolithin B

CAS No. :1139-83-9
Formula : C13H8O3
M.W : 212.20
SMILES Code : O=C1C2=CC=CC=C2C3=CC=C(O)C=C3O1
Synonyms :
NSC 94726; 3-hydroxy Urolithin
MDL No. :MFCD00034338
InChI Key :WXUQMTRHPNOXBV-UHFFFAOYSA-N
Pubchem ID :5380406

Safety of Urolithin B

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • JNK

In Vitro:

Cell Line
Concentration Treated Time Description References
Recombinant human MAO-B enzyme 100 µM 1 hour To evaluate the inhibitory effect of Urolithin B on MAO-B enzyme, results showed low inhibition (<10–20%). Metabolites. 2020 Jun 19;10(6):258
Recombinant human MAO-A enzyme 0.4 and 2 µM 1 hour To evaluate the inhibitory effect of Urolithin B on MAO-A enzyme, results showed an IC50 value of 0.88 µM, displaying a mixed mode of inhibition. Metabolites. 2020 Jun 19;10(6):258
RAW264.7 cells 0, 20, 40, 60, 80, 100, 120, 140 µM 2 and 5 days To assess the effect of UB on cell viability. Results showed that UB concentrations below 100 μM did not affect cell viability. J Cell Mol Med. 2022 Aug;26(16):4428-4439
BV2 cells 10 µM, 20 µM, 40 µM 2 hours pretreatment followed by 24 hours co-treatment withours LPS To evaluate the effect of UB on LPS-induced inflammatory response in BV2 cells. UB significantly suppressed LPS-induced pro-inflammatory factors (TNF-α, IL-1β, IL-6) and M1 polarization marker iNOS expression, and partially restored the protein level of M2 polarization marker CD206. CNS Neurosci Ther. 2025 Apr;31(4):e70379
C2C12 myotubes 15 µM 24 hours Urolithin B enhances the growth and differentiation of C2C12 myotubes by increasing protein synthesis and repressing the ubiquitin–proteasome pathway. J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):583-597
Neuro-2a cells 20, 40, 60 μg/mL 24 hours To evaluate the protective effect of UB on H2O2-induced oxidative injury and apoptosis in neuro-2a cells. Results showed that UB significantly reversed H2O2-induced decrease in cell viability and increase in LDH release, reduced ROS production and apoptosis. Front Pharmacol. 2021 Nov 15;12:768097
Mouse podocytes 100 µM 24 hours or 48 hours Evaluate the effect of high concentration Urolithin B on podocyte viability, results showed 100 µM UB significantly decreased podocyte viability Cells. 2022 Aug 9;11(16):2471
Mouse podocytes 10 µM 24 hours or 48 hours Evaluate the effect of Urolithin B on podocyte viability, results showed 10 µM UB significantly decreased podocyte viability Cells. 2022 Aug 9;11(16):2471
RAW264.7 cells 1, 5, 25 µM 30 minutes to 3 days Inhibited osteoclast-related gene and protein expression, down-regulated ERK/NF-κB signaling pathway Cell Prolif. 2022 Oct;55(10):e13291
K562 cells 25 µMol/mL 48 hours To evaluate the inhibitory effect of Urolithin B on the proliferation of K562 cells, results showed that Urolithin B significantly inhibited the proliferation of K562 cells Int J Mol Sci. 2021 May 22;22(11):5465
Jurkat cells 25 µMol/mL 48 hours To evaluate the inhibitory effect of Urolithin B on the proliferation of Jurkat cells, results showed that Urolithin B significantly inhibited the proliferation of Jurkat cells Int J Mol Sci. 2021 May 22;22(11):5465
Bone marrow macrophages (BMMs) 1, 5, 25 µM 5 days Inhibited RANKL-induced osteoclast differentiation, reduced osteoclast number and area Cell Prolif. 2022 Oct;55(10):e13291
RAW264.7 cells 0, 10, 50, 100 µM 5 days To measure the effect of UB on RANKL-induced intracellular ROS production. Results showed that UB reduced intracellular ROS production in a dose-dependent manner. J Cell Mol Med. 2022 Aug;26(16):4428-4439
RAW264.7 cells 0, 10, 30, 50, 100 µM 5 days To evaluate the effect of UB on RANKL-induced osteoclast differentiation. Results showed that UB inhibited TRAP-positive multinucleated osteoclast formation in a dose-dependent manner. J Cell Mol Med. 2022 Aug;26(16):4428-4439
Human aortic endothelial cells (HAECs) 15 µM 5 minutes and 24 hours To evaluate the effect of Urolithin B on NO release and eNOS activation. Results showed that Urolithin B at 15 μM did not significantly modify NO metabolite production in HAECs after both 5 min and 24 h of incubation. Molecules. 2016 Aug 2;21(8):1009

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 J mice Chronic unpredictable stress (CUS) and lipopolysaccharide (LPS)-induced depression models Intraperitoneal injection 10 mg/kg Once daily for 7 days To evaluate the effect of UB on depression-like behaviors, neuroinflammation, and microglial activation. UB significantly improved CUS- and LPS-induced depression-like behaviors, suppressed microglial activation and neuroinflammation, and restored the expression of SIRT1 and FOXO1 in the hippocampus. CNS Neurosci Ther. 2025 Apr;31(4):e70379
Mice Sciatic nerve denervation model Continuous delivery via mini-osmotic pumps 10 μg/day Continuous delivery for 28 days Urolithin B induces muscle hypertrophy in mice and reduces muscle atrophy after sciatic nerve section. J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):583-597
C57BL/6 mice Ovariectomy (OVX)-induced osteoporosis model Intraperitoneal injection 10, 50 mg/kg Every two days for 8 weeks Alleviated bone loss in OVX mice, reduced the number of NFATc1, MMP9 and TRAP-positive osteoclasts in bone tissues, and decreased serum CTX-1 content Cell Prolif. 2022 Oct;55(10):e13291
Wistar rats Normal-diet fed rats Intraperitoneal (IP) injection 2.5 mg/kg Four times a week for four weeks To evaluate the effects of Urolithin B on liver and kidney functions and gut microbiota composition in normal-diet fed rats. Results showed that Urolithin B improved liver and kidney functions without affecting body weight. Additionally, Urolithin B induced the growth of Akkermansia and influenced the composition of other gut microbiota. Nutrients. 2021 Oct 29;13(11):3885
Human Postpartum women Oral 30 g of walnuts Once daily for three days To evaluate the association of urolithin metabotypes with the restoration of gut microbiota and anthropometric profiles postpartum. Results showed that metabotype-A mothers had a higher proportion of weight loss (≥2 kg) (75%) compared to metabotype-B (54%). The microbiota of metabotype-A mothers changed over the year, unlike metabotype-B, which barely changed. Nutrients. 2019 Sep 3;11(9):2079
Human Healthy individuals Oral 33 g/day Once daily for three days To evaluate the impact of short-term walnut consumption on gut microbiota modulation in healthy individuals, showing that the gut microbiota of UM-B individuals was more sensitive to the walnut intervention. Nutrients. 2019 Oct 16;11(10):2483
C57BL/6 mice D-galactose-induced aging model Intragastric gavage 50, 100, 150 mg/kg/day Once daily for 8 weeks To evaluate the protective effect of UB on cognitive deficits and brain injury in D-galactose-induced aging mice. Results showed that UB significantly ameliorated deficits in learning and memory by inhibiting oxidative stress and neuronal apoptosis, and promoting neuronal survival. Front Pharmacol. 2021 Nov 15;12:768097

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.71mL

0.94mL

0.47mL

23.56mL

4.71mL

2.36mL

47.13mL

9.43mL

4.71mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories